Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment

被引:177
作者
Allen, Matthew R. [1 ]
Burr, David B. [1 ,2 ]
机构
[1] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA
关键词
D O I
10.1016/j.joms.2008.01.038
中图分类号
R78 [口腔科学];
学科分类号
1003 [口腔医学];
摘要
Purpose: An increasing number of reports have implicated bisphosphonates as contributing to osteonecrosis of the jaw. The goal of this study was to evaluate mandible necrosis in beagle dogs treated for 3 years with oral alendronate (ALN). Materials and Methods: Skeletally mature female beagles were treated daily for 3 years with oral doses of vehicle (VEH) or ALN (0.20 or 1.0 mg/kg/day). These doses approximate, on a mg/kg basis, those used for postmenopausal osteoporosis and Paget's disease, respectively. At necropsy, the second molar region of the mandible was excised, stained en bloc with basic fuchsin, and assessed for matrix necrosis and intracortical bone turnover rate using histology. Matrix necrosis was defined as a region greater than 500 mu m(2) that was void of basic fuchsin stain, assessed using both bright-field and confocal microscopy. Results: No animals developed exposed bone lesions in the oral cavity during the 3-year study. Matrix necrosis was observed in 25% of ALN0.2 animals, 33% of ALN1.0 animals, and was noticeably absent from all vehicle animals (P < .05 pooled ALN doses vs VEH). These necrotic regions occurred predominately in the alveolar bone and were clearly void of patent canaliculi. Intracortical bone turnover rate of the alveolar mandible bone region was significantly lower (-75%, P < .05) in ALN-treated animals compared with VEH. Conclusions: Three years of daily oral bisphosphonate treatment reduces bone turnover significantly and increases the incidence of matrix necrosis within the mandible of dogs. (c) 2008 American Association of Oral and Maxillofacial Surgeons.
引用
收藏
页码:987 / 994
页数:8
相关论文
共 36 条
[1]
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate [J].
Allen, Matthew R. ;
Iwata, Ken ;
Phipps, Roger ;
Burr, David B. .
BONE, 2006, 39 (04) :872-879
[2]
*AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144
[3]
Intracortical remodeling in adult rat long bones after fatigue loading [J].
Bentolila, V ;
Boyce, TM ;
Fyhrie, DP ;
Drumb, R ;
Skerry, TM ;
Schaffler, MB .
BONE, 1998, 23 (03) :275-281
[4]
Osteonecrosis of the jaw - Do biphosphonates pose a risk? [J].
Bilezikian, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2278-2281
[5]
BOYCE RW, 1995, J BONE MINER RES, V10, P211
[6]
VALIDITY OF THE BULK-STAINING TECHNIQUE TO SEPARATE ARTIFACTUAL FROM INVIVO BONE MICRODAMAGE [J].
BURR, DB ;
STAFFORD, T .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1990, (260) :305-308
[7]
OSTEOCYTE DEATH AND HIP FRACTURE [J].
DUNSTAN, CR ;
SOMERS, NM ;
EVANS, RA ;
RUBIN ;
OTT ;
SNYDER ;
DAVY ;
SCHAFFLER ;
PARFITT ;
GOLDSTEIN .
CALCIFIED TISSUE INTERNATIONAL, 1993, 53 :S113-S117
[8]
FUNCTIONS OF HAVERSIAN SYSTEM [J].
ENLOW, DH .
AMERICAN JOURNAL OF ANATOMY, 1962, 110 (03) :269-&
[9]
OSTEOCYTE NECROSIS IN NORMAL BONE [J].
ENLOW, DH .
JOURNAL OF DENTAL RESEARCH, 1966, 45 (01) :213-&
[10]
Eriksen EF, 1994, BONE HISTOMORPHOMETR